Xenetic Biosciences Reports Improved Q1 2025 Results

Xenetic Biosciences, Inc. ( (XBIO) ) has released its Q1 earnings. Here is a breakdown of the information Xenetic Biosciences, Inc. presented to its investors.

Xenetic Biosciences, Inc., a biopharmaceutical company based in Framingham, Massachusetts, focuses on advancing innovative immune-oncology technologies to address difficult-to-treat cancers. The company’s proprietary DNase technology aims to improve outcomes of existing treatments by targeting neutrophil extracellular traps involved in cancer progression. In its latest earnings report for the quarter ended March 31, 2025, Xenetic Biosciences reported a 16.1% increase in royalty revenue compared to the same period in 2024, reaching approximately $0.6 million. The company also managed to reduce its net loss by 24.4% year-over-year, totaling $903,141 for the quarter. Key financial highlights include a decrease in research and development expenses by 6.9% and a 21.4% reduction in general and administrative expenses, primarily due to personnel changes. Despite the ongoing geopolitical uncertainties, Xenetic Biosciences remains focused on advancing its DNase technology into clinical trials as an adjunctive therapy for pancreatic carcinoma and other solid tumors. The company anticipates needing additional capital to pursue its long-term business initiatives, but it believes it has access to necessary resources through various financing options.